REFERENCES
- Hegazy I, Khayyal M. Intestinal microsomal enzyme induction by rifampicin. Chemioterapia 1987; 6: 325–327.
- Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24: 796–801.
- Rowland IR. Interactions of the gut microflora and the host in toxicology. Toxicol Pathol 1988; 16: 147–153.
- Hooymans PM, Merkus FW. Current status of cardiac glycoside drug interactions. Clin Pharm 1985; 4: 404–413.
- Rowland IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev 1988; 19: 234–261.
- Ahr HJ, Boberg M, Krause HP, et al. Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism, and excretion after single administration of [14C] acarbose to rats, dogs and man. Arzneim Forsch/Drug Res 1989; 39: 1254–1260.
- Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985; 63: 1205–1211.
- Strolin-Benedetti M, Dostert P. Introduction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994; 102: 101–105.
- Musch E, Loos U, Schwabe HK. Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide. Pneumologie 1990; 44: 486–487.
- Li RC, Narang PK, Poggesi I, Strolin-Benedetti M. A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. Biopharm Drug Dispos. 17, 223–236 (1996).
- Strolin-Benedetti M, Efthymiopoulos C, Sassella D, Moro E, Repetto M. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990; 20: 1113–1119.
- Nahata MC, Fan-Havard P, Barson WJ, Bartkowski HM, Kosnik EJ. Pharmacokinetics, cerebrospinal fluid concen-tration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. Eur J Clin Pharmacol 1990; 38: 515–517.
- Gibaldi M, Perrier E. Noncompartmental analysis based on statistical moment theory. In Pharmacokinetics, 2nd ed (J. Swarbrick, ed.), New York: Marcel Dekker, Inc., 1982: 409-416.
- Huang R, Okuno H, Takasu M, Shiozaki Y, Inoue K. Comparision of effects of xenobiotics on extrahepatic and hepatic microsomal drug-metabolizing enzymes in mice. Environ Toxicol Pharmacol 1996; 1: 123–130.
- Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450 IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878.
- Anufrieva RG, Zaslavskaia PL, Shenderov BA. Changes in the microbial ecology and morphology of large intestine biofilm in albino rats under the influence of rifampicin. Antibiot Khimioter 1989; 34: 457–462.
- Mitrokhin SD, Shenderov BA. Microbiological and bio-chemical indices of changes in microbial ecology of rat large intestine under the effect of rifampicin. Antibiot Khimioter 1989; 34: 448–452.